MX2023010858A - Mejora de la cicatrización de heridas con anticuerpos anticeramidas. - Google Patents

Mejora de la cicatrización de heridas con anticuerpos anticeramidas.

Info

Publication number
MX2023010858A
MX2023010858A MX2023010858A MX2023010858A MX2023010858A MX 2023010858 A MX2023010858 A MX 2023010858A MX 2023010858 A MX2023010858 A MX 2023010858A MX 2023010858 A MX2023010858 A MX 2023010858A MX 2023010858 A MX2023010858 A MX 2023010858A
Authority
MX
Mexico
Prior art keywords
wound
wound healing
ceramide antibodies
antibodies
healing enhancement
Prior art date
Application number
MX2023010858A
Other languages
English (en)
Spanish (es)
Inventor
Richard Kolesnick
Julia Busik
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2023010858A publication Critical patent/MX2023010858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023010858A 2021-03-16 2022-03-15 Mejora de la cicatrización de heridas con anticuerpos anticeramidas. MX2023010858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163161758P 2021-03-16 2021-03-16
PCT/US2022/020385 WO2022197703A1 (en) 2021-03-16 2022-03-15 Wound healing enhancement with anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
MX2023010858A true MX2023010858A (es) 2023-11-23

Family

ID=83321040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010858A MX2023010858A (es) 2021-03-16 2022-03-15 Mejora de la cicatrización de heridas con anticuerpos anticeramidas.

Country Status (10)

Country Link
US (1) US20240158487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308231A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511079A (cg-RX-API-DMAC7.html)
KR (1) KR20230162788A (cg-RX-API-DMAC7.html)
CN (1) CN117320750A (cg-RX-API-DMAC7.html)
BR (1) BR112023018758A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212333A1 (cg-RX-API-DMAC7.html)
IL (1) IL305920A (cg-RX-API-DMAC7.html)
MX (1) MX2023010858A (cg-RX-API-DMAC7.html)
WO (1) WO2022197703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12655229B2 (en) 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (en) * 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
SG11201700787XA (en) * 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
US12655229B2 (en) * 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Also Published As

Publication number Publication date
CA3212333A1 (en) 2022-09-22
CN117320750A (zh) 2023-12-29
WO2022197703A1 (en) 2022-09-22
US20240158487A1 (en) 2024-05-16
IL305920A (en) 2023-11-01
EP4308231A4 (en) 2025-01-29
KR20230162788A (ko) 2023-11-28
JP2024511079A (ja) 2024-03-12
EP4308231A1 (en) 2024-01-24
BR112023018758A2 (pt) 2023-11-28

Similar Documents

Publication Publication Date Title
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
ECSP21022299A (es) Anticuerpos de anti-cd33 y métodos para usarlos
UY39118A (es) ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)
CL2021003535A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019)
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
ECSP22094536A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
CL2022001554A1 (es) Anticuerpos anti-mertk y métodos de uso de los mismos
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
CO2023002034A2 (es) Moléculas de unión a antígeno multi-específicas contra el vih y métodos de uso
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
CL2023002326A1 (es) Anticuerpos contra la proteína espicular de coronavirus
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
MX2021000889A (es) Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
ECSP22056627A (es) Anticuerpos contra la integrina alfa 11 beta 1
MX2024015304A (es) Terapias combinadas con un anticuerpo antifactor xi/factor xia
CL2025002123A1 (es) Anticuerpos anti- cmet y métodos de uso
BR112021020612A2 (pt) Métodos para tratamento de sujeitos com artrite psoriática
BR112023018758A2 (pt) Intensificação de cicatrização de ferida com anticorpos anticeramida
UY40481A (es) Composición líquida de dalbavancina
UY40482A (es) Composición líquida de dalbavancina.
MX2024001104A (es) Medicamento para el tratamiento y/o prevencion de cancer.
AR120739A1 (es) Anticuerpos anti-mertk y métodos de uso de los mismos
CL2025002547A1 (es) Anticuerpo anti-proteína espiga del sars-cov-2; método de producción; composición que lo comprende; y uso.
AR120759A1 (es) Anticuerpos anti-coronavirus y métodos de uso